ZTS Stock Analysis: Buy, Sell, or Hold?
ZTS - ZOETIS INC.
$124.82
3.10 (2.55%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 12, 2026
12d
Get Alerted When ZTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZTS shows positive signals but monitor for confirmation. Market pricing in 1.0% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ZTS shows positive signals but monitor for confirmation. Market pricing in 1.0% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$164.65
Based on 5.6% avg growth
INTRINSIC VALUE TODAY
$102.23
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZTS is currently trading at $124.82, which is considered fair relative to its 30-day fair value range of $123.46 to $126.98. The stock's valuation (Forward PE: 17.9) is in line with its historical norms (18.4). Remarkably, the market is currently pricing in an annual earnings decline of 1.0% over the next few years. This pessimistic expectation contrasts with the company's recent 8.5% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ZTS is in a strong downtrend. The price is approaching resistance at $127.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $154.78 (+27.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZTS is in a strong downtrend. The price is approaching resistance at $127.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $154.78 (+27.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$123.46 -
$126.98
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 27.2% below Wall St target ($154.78)
Fair Price Analysis
30-Day Fair Range
$123.46 -
$126.98
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$120.06
Resistance Level
$127.12
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
17.90
Wall Street Target
$154.78
(+27.2%)
Revenue Growth (YoY)
0.5%
Earnings Growth (YoY)
8.5%
Profit Margin
28.2%
Valuation Discount vs History
-1.0% cheaper
PE vs Historical
17.9 vs 18.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.0%
(market-implied from PE analysis)
1-Year Target
$120.50
(-1%)
2-Year Target
$119.30
(-2%)
3-Year Target
$118.10
(-3%)
3-Yr Target (if PE normalizes)
(PE: 18→18)
$121.41
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 7.3%)
$187.12
(+54%)
Base:
(SPY PE: 17.9, Growth: 7.3%)
$150.20
(+23%)
Bear:
(PE: 15.2, Growth: 7.3%)
$127.67
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 21.04 | Current EPS (TTM): $5.94
Bull Case
$157.36
(+29%)
Analyst growth 14.5%, PE expands to 23.1
Base Case
$143.06
(+18%)
Market implied 14.5%, PE stable at 21.0
Bear Case
$84.97
(-30%)
Severe decline -20.0%, PE contracts to 17.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.9 to 18.4
Stabilization Target:
$125.12
(+2.8%)
PE Expansion Potential:
+2.8%
Last updated: January 30, 2026 5:40 PM ET
Data refreshes hourly during market hours. Next update: 6:40 PM
Data refreshes hourly during market hours. Next update: 6:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZTS showing a specific setup today?
Insider Activity (6 Months)
7
Buys
5
Sells
+
Net
NEUTRAL
Recent Transactions
Rick Larsen
SELL
2025-10-06
Ro Khanna
SELL
2025-09-29
Ro Khanna
BUY
2025-09-26
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$179 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$84 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$35 | 54 HOLD |
Advanced ZTS Option Strategies
Professional options setups generated by AI based on today's ZTS price and gamma walls.
